Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
| Autor: | Naga Chalasani, Lauren Pavlik, Paul A. Ardayfio, Arie Regev |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
media_common.quotation_subject Disease Toxicology Bioinformatics 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Non-alcoholic Fatty Liver Disease Medicine Animals Humans Pharmacology (medical) 030212 general & internal medicine media_common Pharmacology Liver injury medicine.diagnostic_test business.industry Fatty liver nutritional and metabolic diseases medicine.disease digestive system diseases Fatty Liver Drug development Liver Liver biopsy Disease Progression Steatosis Steatohepatitis Chemical and Drug Induced Liver Injury business Biomarkers |
| Zdroj: | Drug safety. 42(6) |
| ISSN: | 1179-1942 |
| Popis: | Drug-induced steatosis (DIS) and drug-induced steatohepatitis (DISH) are two of several types of drug-induced liver injury (DILI). They can be caused by various drugs and may present as acute, potentially lethal disorders or as chronic slowly progressive liver injury. Despite the fact that they are distinct disorders, the slow progressive forms of DIS and DISH are often confused with or misdiagnosed as non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), which are much more common and, by definition, not caused by drugs. Currently the only way to identify DIS is via imaging studies or a liver biopsy, while DISH can be identified only through liver biopsy. In addition, diagnosis of either DIS or DISH requires an exhaustive clinical evaluation and comprehensive causality assessment to rule out other possible causes and determine the association with the suspected drug. Furthermore, it is difficult, using existing methods, to monitor the progression of DIS and DISH and to determine the underlying mechanism. Therefore, there is a great unmet need for non-invasive biomarkers that will be able to identify the development of DIS or DISH during drug development and to monitor for progression or regression of the disorder during treatment or following drug discontinuation. Recent developments in the fields of NAFLD and NASH have introduced several novel biomarkers that show promise for the diagnosis, monitoring, and severity assessment of these common diseases. Given the significant overlap in possible underlying mechanisms and histological pattern between NAFLD/NASH and DIS/DISH, these postulated NAFLD and NASH biomarkers may have a potential application to DIS and DISH. This article reviews the existing medical literature and other publically available information pertaining to novel serum biomarkers for NAFLD and NASH, and explores the concurrent identification of these biomarkers for DIS and DISH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink